KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Accumulated Depreciation (2020 - 2021)

Twist Bioscience has reported Accumulated Depreciation over the past 2 years, most recently at $35.4 million for Q3 2021.

  • Quarterly Accumulated Depreciation rose 20.16% to $35.4 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $35.4 million through Sep 2021, up 20.16% year-over-year, with the annual reading at $35.4 million for FY2021, 20.16% up from the prior year.
  • Accumulated Depreciation was $35.4 million for Q3 2021 at Twist Bioscience, up from $29.5 million in the prior quarter.
  • Over five years, Accumulated Depreciation peaked at $35.4 million in Q3 2021 and troughed at $29.5 million in Q3 2020.